共 145 条
[1]
Rüping M(2008)Patients at high risk of invasive fungal infections: when and how to treat Drugs 68 1941-1962
[2]
Vehreschild J(2004)Burden of hospitalization of patients with Candida and Aspergillus infections in Australia Int J Infect Dis 8 111-120
[3]
Cornely O(2002)Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 225-234
[4]
Slavin M(2011)European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update Bone Marrow Transplant 46 709-718
[5]
Fastenau J(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 52 e56-93
[6]
Sukarom I(2010)Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis Clin Ther 32 637-648
[7]
Mavros P(2004)Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 1391-1402
[8]
Crowley S(2007)Early clinical experience with anidulafungin at a large tertiary care medical center Pharmacotherapy 28 64-73
[9]
Gerth W(2003)Voriconazole Clin Ther 25 1321-1381
[10]
Walsh T(2009)Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia J Antimicrob Chemother 63 197-208